Portfolio update: Added a small position in SCNX (Scienture Holdings Inc.)

Good past few days for my portfolio. Finally UNCY is moving in anticipation of PDUFA date (June 28).

I took a small position in SCNX (Scienture Holdings Inc.). This is a $14-million-capitalization monster :) Obviously, joking. But the current price really does not make sense to me. On March 18, 2025, the company got U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

ArbliTM is meant for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes. ArbliTM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market.

So, in my mind, if the company takes even $100 million in sales, with its current market cap this will give a very low P/S ratio. Targeting a P/S ratio of 1, should push the stock higher.

The company announced manufacturing and supply chain readiness for Arbli™, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

The crowd seems to start taking notice of the stock as it is trying to pop over the past 3 trading days.

---

Disclaimer: As usual, trade at your own risk. I own SCNX stock. I do not suggest you should buy any of the stocks I write about. As usual, please do your own due diligence before investing your own money in any of the stocks I write about. The above analysis is quite basic and just gives ideas for further research. A much deeper analysis is required for each stock, including the analysis of operations, debt, etc. I may sell any of the stocks I say I currently own at any moment before it reaches the targets that I set or keep them for even when they reach the target.